1st-Gen TRK Inhibitors
First-Generation TRK Inhibitors: Clinical Evidence and Indications

Released: October 15, 2021

Expiration: October 14, 2022

George D. Demetri
George D. Demetri, MD
Alexander E Drilon
Alexander E Drilon, MD

Activity

Progress
1
Course Completed

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:

  • Basket trials leading to FDA approvals of larotrectinib and entrectinib
  • Current pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLC
  • Sequencing treatment with TRK inhibition in patients with solid tumors
  • Clinically relevant similarities and differences between larotrectinib and entrectinib